Identification of formononetin as the active compound of CR‐SR in hepatocellular carcinoma treatment: An integrated approach combining network pharmacology and weighted gene co‐expression networks

Abstract

AbstractHepatocellular carcinoma (HCC) is a life‐threatening disease for which there is no cure. Traditional Chinese medicine is a treasure trove of Medicinals that has been used for thousands of years. In China, the traditional herb pair, Curcumae Rhizoma and Sparganii Rhizoma (CR‐SR) represent a classic herbal combination used for the treatment of HCC. However, the drug targets and pharmacological mechanism of action of CR‐SR in the treatment of HCC are unclear. To address this, we screened the active components and drug targets of CR‐SR from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database and a high‐throughput experiment‐ and reference‐guided database of traditional Chinese medicines (HERB database). Combined with the weighted co‐expression network analysis of dataset GSE76427, we constructed an active component‐target‐disease regulatory network. It was found that CR‐SR's active components for HCC treatment included trans‐gondoic acid, beta‐sitosterol, stigmasterol, hederagenin, and formononetin. These compounds specifically targeted the genes Estrogen Receptor 1 (ESR1), Cyclin A2 (CCNA2), Checkpoint Kinase 1 (CHEK1), and Nuclear Receptor Coactivator 2 (NCOA2). ESR1, CCNA2, and CHEK1 genes showed significant differences in survival prognosis, expression levels, and statistical significance during the pathological stage. Moreover, their high affinity for formononetin was determined through molecular docking analysis. Cell assays and high‐throughput sequencing were performed to reveal that the inhibitory effect of formononetin on HepG2 cell proliferation was related to hepatocyte metabolism and cell cycle regulation‐related pathways. This study provides insights into potential HCC treatments.